Bertis and Innoquest Diagnostics have entered into a strategic partnership to bring Bertis’ technology to the Southeast Asian market.
On July 3, Bertis, a company specializing in proteomics-based precision medicine technology, led by CEOs Dong-young Noh and Seung-man Han, announced the signing of a strategic partnership agreement with Innoquest Diagnostics, the leading clinical diagnostics laboratory in Singapore.
Innoquest is a leading independent and internationally accredited diagnostics provider in Singapore. It is a subsidiary of Pathology Asia, one of Southeast Asia’s largest networks of independent laboratories. With operations across Singapore, Malaysia, Vietnam, the Philippines, Thailand, Indonesia, and Australia, Pathology Asia collectively serves a population of over 500 million. With its large-scale infrastructure and regional reach, the group is well-positioned as a key enabler of accessible, high-volume cancer screening throughout Southeast Asia. This partnership aims to establish the local testing infrastructure for Bertis’ proteomics-based blood test for early breast cancer detection, while laying the foundation for service expansion into new Asia-Pacific markets.
Under this strategic collaboration, Bertis will provide its mass spectrometry-based proteomic analysis technology, which powers its CHECK series of blood-based diagnostic tests, including MASTOCHECK® as well as additional pipeline tests targeting other cancers, such as pancreatic and ovarian cancer.
Innoquest Diagnostics will operate the test at its facilities and handle its distribution and commercialization in Singapore. This collaboration enables Bertis to establish a strong operational footprint to meet the growing demand for advanced diagnostic solutions. The two companies plan to sequentially expand the service through the Pathology Asia network of laboratories into other Southeast Asian countries including Indonesia, Malaysia, Thailand, Vietnam, the Philippines, Australia, and Hong Kong.
Through this partnership, Bertis aims to accelerate the localization and adoption of its cancer early detection technologies further strengthening the global competitiveness of its proteomics-based precision diagnostic platform. Southeast Asia presents a significant unmet need for early cancer detection given high cancer incidence rates coupled with low screening coverage. Blood-based diagnostics such as
MASTOCHECK® offer a compelling, accessible solution for this region.
Seung-man Han, CEO of Bertis, stated, “This partnership reflects the trust and executional experience we’ve built in Singapore around proteomics technologies. More than just a distribution deal, it marks a strategic entry into the Southeast Asia cancer diagnostics market based on our proprietary technology. We hope that MASTOCHECK® and our broader portfolio of proteomics-based early detection solutions will make a meaningful contribution to improving cancer care across diverse healthcare systems.”
Thomas Halusa, CEO of Innoquest Diagnostics, added, “We are excited to partner with Bertis to bring innovative, blood-based cancer screening tools to Singapore and the broader region. This collaboration aligns with our commitment to advancing accessible, science-led diagnostic solutions and reinforces our role as a region’s partner of choice for global medical technology innovators.”
About Innoquest Diagnostics
Innoquest Diagnostics Pte Ltd emerged from the merger of Innovative Diagnostics and Quest Laboratories, which have served the Singaporean medical community for over 25 years. With eight facilities across the country, Innoquest stands as Singapore’s leading independent diagnostics provider, internationally accredited and trusted to process over three million patient test referrals each year. Innoquest aspires to be Singapore’s preeminent clinical diagnostics provider, by developing enduring partnerships and fostering deep engagement with the medical provider community. For more information, please visit our website https://www.innoquest.com.sg/ or follow us on LinkedIn
https://www.linkedin.com/company/innoquest-diagnostics.
About Pathology Asia
Pathology Asia Holdings Pte Ltd is a leading diagnostic service provider in Southeast Asia, headquartered in Singapore. The Pathology Asia group includes leading diagnostic laboratories in Singapore, Malaysia, Vietnam, Philippines, Thailand, Indonesia, and Australia, with a specialised genomics division and a digital health division. Pathology Asia’s goal is to enable affordable access to high quality and comprehensive diagnostic service to the entire population of Southeast Asia. For more information, please visit our website https://www.pathologyasia.com/ or follow us on LinkedIn https://www.linkedin.com/company/pathology-asia.
Contacts
Head of Group Marketing
Camille Cyncynatus
camille.cyncynatus@pathologyasia.com
Marketing Manager
Chai San Ho
About Bertis
Bertis is a pioneer of proteomics-based disease detection and therapy companion diagnostics. Bertis’ capabilities range from cancer, disorder biomarker discovery, low-cost diagnostics manufacturing and analysis services. Since its inception in 2014, the company has been focused on developing and improving technologies for early diagnosis solutions with the most advanced quantitative proteomics research, precision medicine based on companion diagnostic markers, and target discovery for oncology drug development and personalized treatment. Flagship solutions include MASTOCHECK®, the world’s first proteomics-based blood test solution for early breast cancer detection, and PASS (Pan-omics Analysis Service & Solution), a platform for integrative analysis of multi-omics data. For more information, please visit our website www.bertis.com or follow us on LinkedIn www.linkedin.com/company/bertis-inc.
Contacts
Marketing Manager
Geumhee Lee
geumhee.lee@bertis.com
Assistant Manager
Daeun Jang